About Cornerstone Therapeutics
Cornerstone Therapeutics is a company based in Cary (United States) founded in 2003 was acquired by Chiesi Pharmaceuticals in February 2014. The company has 318 employees as of December 31, 2022. Cornerstone Therapeutics has completed 2 acquisitions, including Cardiokine and EKR Therapeutics. Cornerstone Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
- Headquarter Cary, United States
- Employees 318 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$30 M (USD), Debt – Conventional
Jul 02, 2012
- Investors
-
Employee Count
318
as on Dec 31, 2022
-
Investments & Acquisitions
Cardiokine
& 1 more
-
Acquired by
Chiesi Pharmaceuticals
(Feb 04, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cornerstone Therapeutics
Investors in Cornerstone Therapeutics
Cornerstone Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Chiesi Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas
|
Locked | Locked | Locked |
Investor details for Cornerstone Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cornerstone Therapeutics
Cornerstone Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cardiokine and EKR Therapeutics.
Investment portfolio details for Cornerstone Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Oncology supportive care and generic products are manufactured and commercialized.
|
Locked | Locked | 2005 | Locked | |
|
Pharmaceuticals for cardiovascular disease prevention and treatment are developed.
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Cornerstone Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cornerstone Therapeutics
Detailed financials for Cornerstone Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cornerstone Therapeutics Comparisons
Peer comparison for Cornerstone Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cornerstone Therapeutics
Cornerstone Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
|
|
| Locked | Locked | Locked |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
|
| Locked | Locked | Locked |
Respiratory disease drugs for asthma and COPD are developed.
|
Detailed competitors of Cornerstone Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cornerstone Therapeutics
Complete news archive for Cornerstone Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cornerstone Therapeutics
Cornerstone Therapeutics was founded in 2003 and raised its 1st funding round 9 years after it was founded.
Cornerstone Therapeutics is headquartered in Cary, United States. It is registered at Cary, North Carolina, United States.
As of Dec 31, 2022, the latest employee count at Cornerstone Therapeutics is 318.
Cornerstone acquired by Chiesi Farmaceutici SpA is a pharmaceutical firm with five marketed products. The products include ZYFLO, an orally ingested treatment for asthma, CARDENE (nicardipine), an injected treatment for hypertension, CUROSURF which is a lung surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in infants, PERTZE that is used to treat exocrine pancreatic insufficiency (EPI), BETHKIS another CF-related treatment (for Pseudomonas aeruginosa - PA) and generic version of Tussionex (an allergy treatment).
Cornerstone Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Cornerstone Therapeutics has made 2 acquisitions, including Cardiokine, and EKR Therapeutics.
Cornerstone Therapeutics has 1 investor. Key investors include Chiesi Pharmaceuticals.